Core Biogenesis has announced the launch of Peaureva, a biotechnology-derived active ingredient designed to improve hair density and scalp health in 28 days.
Core Biogenesis recently launched Peaureva, a biotechnology-derived cosmetic active designed to target the biological causes of thinning hair and aging scalp. This new ingredient will be presented at In-Cosmetics Global 2026 in Paris.
#1TP8A new active ingredient targeting biological mechanisms
Unlike traditional cosmetic ingredients that focus primarily on the appearance of hair fibers, Peaureva has been developed to address the biological mechanisms influencing follicle activity and scalp health. Hair thinning is increasingly perceived as a multifactorial process, resulting from a number of biological changes in the scalp microenvironment.
Core Biogenesis identifies five biological factors related to scalp aging that contribute to the progressive decrease in hair density:
- dysregulation of the hair cycle - decreased dermal papillae signaling - declining microvascular support around follicles - progressive thinning of hair fibers - deterioration of the scalp's barrier environment
Peaureva has been designed to support these interconnected pathways using oleosome-stabilized biomimetic growth factor technology.
Clinical results in 28 days
Peaureva was evaluated in a randomized, double-blind, placebo-controlled clinical trial involving 40 volunteers. Instrumental measurements showed statistically significant improvements over placebo on several scalp and hair parameters.
After 28 days, active treatment showed:
- 33.6 % increase in capillary density - 14.0 % increase in anagen/telogen ratio - 5.0 % increase in hair shaft thickness - 17.5 % increase in scalp hydration
An increase in the anagen/telogen ratio indicates a shift in follicles towards the active growth phase, while improvements in fiber density and thickness contribute to a fuller hair appearance.
Most cosmetic actives designed to treat hair thinning typically require 90-120 days of continuous use to show modest improvements. The early improvements observed with Peaureva highlight the potential of biotechnology-based approaches targeting follicular signaling pathways.
